SG3 Management’s BioNTech BNTX Stock Holding History

SG3 Management’s Portfolio BNTX Stock Details BNTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-7,200	Closed	-$1.08M	–	41
2022 Q4	$1.08M	Buy	+7,200	New	+$1.11M	0.16%	81
2022 Q3	–	Sell	-3,000	Closed	-$459K	–	313
2022 Q2	$447K	Sell	3,000 -16,000	-84%	-$2.44M	0.05%	218
2022 Q1	$3.24M	Buy	+19,000	New	+$3.19M	0.09%	207
2021 Q2	–	Sell	-1,000	Closed	-$109K	–	1046
2021 Q1	$109K	Sell	1,000 -8,000	-89%	-$850K	﹤0.01%	1041
2020 Q4	$734K	Buy	+9,000	New	+$884K	0.01%	630

Other funds holding BNTX

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

Flossbach Von Storch Cologne, Germany $21.4B AUM 8.31% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

AGA

Altrinsic Global Advisors Stamford, Connecticut $2.79B AUM 7.25% 1-Year Est. Return

SG3 Management's BNTX Position: Q1 2023 in Review

SG3 Management sold out of BioNTech (BNTX) in Q1 2023, closing a stake of 7,200 shares — an estimated $1.08M sold.

SG3 Management first reported a position in BNTX in Q4 2020 and held it in 5 quarters. The position peaked at $3.24M in Q1 2022. 282 funds tracked by Wall St. Rank hold BNTX as of Q1 2023.

SG3 Management reported no remaining BioNTech position as of Q1 2023 after selling out during the quarter.
SG3 Management sold 7,200 BioNTech shares in Q1 2023, an estimated $1.08M.
SG3 Management first reported a position in BioNTech in Q4 2020 and held it in 5 quarters.
SG3 Management's BioNTech position peaked at $3.24M in Q1 2022.
282 funds tracked by Wall St. Rank held BioNTech as of Q1 2023.

Based on SG3 Management's 13F filing for Q1 2023, filed 15 May 2023.